Autolus Therapeutics PLC (AUTL) 13F Positioning & Ownership Changes (Q2 2026)

AUTL ranks #5017 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

AUTL is a disclosed holding of Stephen Schwarzman (Blackstone Group), one of the tracked superinvestors on AlphaSMO — it makes up 0.1% of that fund's own 13F portfolio.

AUTL is a top-conviction position for Syncona Portfolio Ltd — at 100.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in AUTL belongs to Mak Capital One LLC, but the position matters far more to Syncona Portfolio Ltd, who has 100.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

UBS Group AG has added to its AUTL position for two straight quarters, increasing it by $681.8K to reach $2.4M today.

Susquehanna International Group, LLP has trimmed its AUTL position for two straight quarters, cutting it by $962.7K while still holding $283.6K.

AUTL is down 3% today, and institutions have been net sellers of $2.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AUTL reported a net loss of $280.2M over the trailing twelve months.

• Not yet profitable — net loss of $280.2M over the trailing twelve months
• Revenue grew 292.2% year over year
• Net income declined year over year, from -$227.8M to -$280.2M
• Operating cash flow was negative, using $283.6M in cash
• Current ratio of 5.94x — enough short-term assets to cover short-term liabilities
• Liabilities run 2.31x equity — a highly leveraged balance sheet worth noting